Loading…
Amphastar Pharmaceuticals, Inc. is projected to rise to $20.50 by 2027, a +10% move from its current price of $18.72. AMPH is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $18.23 | $18.73 | $19.24 | +0.05% |
| Jul 15 | $18.04 | $18.74 | $19.47 | +0.09% |
| Jul 16 | $17.89 | $18.75 | $19.64 | +0.14% |
| Jul 17 | $17.77 | $18.75 | $19.79 | +0.19% |
| Jul 18 | $17.67 | $18.76 | $19.93 | +0.23% |
| Jul 19 | $17.57 | $18.77 | $20.05 | +0.28% |
| Jul 20 | $17.49 | $18.78 | $20.17 | +0.33% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $17.49 | $18.78 | $20.17 | +0.33% |
| Week 2 | $17.03 | $18.84 | $20.84 | +0.65% |
| Week 3 | $16.71 | $18.90 | $21.39 | +0.98% |
| Week 4 | $16.44 | $18.96 | $21.87 | +1.31% |
| Week 5 | $16.22 | $19.03 | $22.32 | +1.64% |
| Week 6 | $16.03 | $19.09 | $22.73 | +1.97% |
| Week 7 | $15.86 | $19.15 | $23.13 | +2.30% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Amphastar Pharmaceuticals, Inc. is a bio-pharmaceutical company that develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. Its portfolio includes BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose.
The company also provides Cortrosyn, a Lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; and emergency syringe products, including atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate. In addition, it offers Albuterol sulfate inhalation aerosol for the treatment or prevention of bronchospasm; Iron sucrose injection, an iron replacement product for the treatment of iron deficiency anemia in patients with chronic kidney disease; Teriparatide injection for managing daily osteoporosis therapy; and Ipratropium Bromide HFA inhalation aerosol, an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease. Further, the company provides active pharmaceutical ingredient (API) products, such as Recombinant Human Insulin and porcine insulin API.
The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
Amphastar Pharmaceuticals, Inc. is currently trading at $18.88 with a market cap of $832.47M and ranks 2675.
A major floor 15.2% below — a decisive break under it would weaken the trend.
The nearest floor, 3.2% below — buyers have tended to step in here.
The nearest ceiling, 16.3% above — a clean break opens room to run.
A major ceiling 28.4% above — clearing it would confirm fresh momentum.
Key AMPH support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of AMPH market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $19.26 | Sell | $19.19 | Sell |
| MA 10 | $19.87 | Sell | $19.52 | Sell |
| MA 20 | $19.86 | Sell | $19.66 | Sell |
| MA 50 | $19.66 | Sell | $19.93 | Sell |
| MA 100 | $20.57 | Sell | $20.96 | Sell |
| MA 200 | $23.44 | Sell | $23.01 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 42.83 | Neutral |
| Stoch RSI (14) | 7.70 | Buy |
| CCI (20) | -109.67 | Sell |
| Williams %R (14) | -88.70 | Info |
| MACD (12,26,9) | -0.17 | Sell |
| ROC (12) | -4.15 | Sell |
| Bollinger %B (20,2) | 0.17 | Neutral |
| Stochastic %K (14) | 11.30 | Buy |
| TRIX (15) | 0.08 | Buy |
| Awesome (5,34) | -0.24 | Sell |
| Ultimate (7,14,28) | 34.21 | Neutral |
| Momentum (10) | -2.32 | Sell |
| Aroon Osc (25) | 64.00 | Buy |
| Hull MA (9) | 18.77 | Sell |
| ADX (14) | 11.10 | Neutral |
| ATR (14) | 0.52 | Info |
The near-term technical picture remains bearish. RSI14 is 40, signaling modest negative momentum. The 50-day simple moving average (SMA50) sits at $19.78 while the 200-day simple moving average (SMA200) sits at $23.53. Support is marked at $18.12 and resistance at $21.78. The 30-day price range runs from $15.65 to $22.77.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $16.87 | $18.72 | $23.85 | 0% | Neutral | |
| $16.34 | $20.50 | $27.20 | +10% | Neutral | |
| $15.87 | $20.47 | $28.17 | +9% | Neutral | |
| $18.93 | $24.98 | $35.37 | +33% | Bullish | |
| $22.18 | $29.85 | $43.31 | +59% | Bullish | |
| $23.28 | $31.92 | $47.29 | +71% | Bullish | |
| $26.21 | $36.55 | $55.18 | +95% | Bullish | |
| $26.49 | $37.54 | $57.65 | +101% | Bullish | |
| $26.00 | $37.42 | $58.37 | +100% | Bullish | |
| $27.73 | $40.48 | $64.08 | +116% | Bullish | |
| $40.11 | $62.54 | $105.26 | +234% | Bullish | |
| $72.79 | $127.14 | $233.93 | +579% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $16.87 | $18.72 | $22.14 | +0.00% |
| August 2026 | $16.01 | $18.89 | $22.88 | +0.90% |
| September 2026 | $16.44 | $19.53 | $23.92 | +3.39% |
| October 2026 | $16.19 | $19.35 | $23.91 | -0.93% |
| November 2026 | $15.69 | $18.85 | $23.48 | -2.57% |
| December 2026 | $15.75 | $19.01 | $23.85 | +0.84% |
Click any year to see its month-by-month AMPH forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, AMPH is projected to trade between $16.87 and $23.85, averaging $18.72 — a potential gain of 0% from today's $18.72. A consolidation phase looks the most probable path here.
Amphastar Pharmaceuticals, Inc.'s 2027 outlook centres on $20.50, within a $16.34 to $27.20 range. That is up +10% on the projected 2026 average. That marks a +10% change versus current levels. Price action looks broadly range-bound.
By 2028, AMPH could reach as high as $28.17, with a base case around $20.47 and support toward $15.87 — roughly +9% from $18.72. A consolidation phase looks the most probable path here.
Expect AMPH to range from $18.93 to $35.37 through 2029. The $24.98 average target implies a +33% move from current prices. That is up +22% on the projected 2028 average. Momentum favours further upside here.
The AMPH price prediction for 2030 points to an average of $29.85 (low $22.18, high $43.31) — a potential gain of +59% on today's $18.72. Buyers look set to stay in control over this stretch.
In 2031, AMPH is projected to trade between $23.28 and $47.29, averaging $31.92 — a potential gain of +71% from today's $18.72. That is up +7% on the projected 2030 average. Momentum favours further upside here.
Amphastar Pharmaceuticals, Inc.'s 2032 outlook centres on $36.55, within a $26.21 to $55.18 range. That is up +15% on the projected 2031 average. That marks a +95% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, AMPH could reach as high as $57.65, with a base case around $37.54 and support toward $26.49 — roughly +101% from $18.72. Momentum favours further upside here.
Expect AMPH to range from $26.00 to $58.37 through 2034. The $37.42 average target implies a +100% move from current prices. That is 0% versus the projected 2033 average. Buyers look set to stay in control over this stretch.
The AMPH price prediction for 2035 points to an average of $40.48 (low $27.73, high $64.08) — a potential gain of +116% on today's $18.72. Momentum favours further upside here.
In 2040, AMPH is projected to trade between $40.11 and $105.26, averaging $62.54 — a potential gain of +234% from today's $18.72. That is up +54% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Amphastar Pharmaceuticals, Inc.'s 2050 outlook centres on $127.14, within a $72.79 to $233.93 range. That is up +103% on the projected 2040 average. That marks a +579% change versus current levels. Momentum favours further upside here.
Investing $1,000 in AMPH today (≈ 53.418803 AMPH) could be worth
$6,791.73
+$5,791.73 (+579%) by 2050 · US Dollar
Based on the average projected AMPH price of $127.14 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in AMPHwould be worth at today's price.
$1,000 invested in AMPH on Jul 10, 2025 (≈ 45.024765 AMPH) would be worth
$842.86
-$157.14 (-15.7%) today · 0.84× · US Dollar
Based on a AMPH entry price of $22.21 vs. today's $18.72.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $19.64 | $953.16 | -4.7% |
| 1 month ago | $20.29 | $922.62 | -7.7% |
| 3 months ago | $20.37 | $919 | -8.1% |
| 6 months ago | $29.4 | $636.73 | -36.3% |
| 1 year ago | $22.21 | $842.86 | -15.7% |
| All time (5.0y) ago | $20.01 | $935.53 | -6.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our AMPH forecast.
Our base-case forecast reaches $37.00 around 2033.
Implied market cap at $37.00: $1.63B
The multi-year forecast shows bullish upside in the longer term. The 2026 forecast is min $16.87, avg $18.88, max $24.07 with ROI 0 and Neutral sentiment; 2027 min $16.12, avg $20.34, max $27.18 with ROI 7.7 and Neutral sentiment; 2028 min $15.46, avg $20.07, max $27.87 with ROI 6.3 and Neutral sentiment. By 2029 the avg rises to $24.47 (bullish), and 2030 the avg is $29.04 with ROI 53.8 (bullish).
Looking further, 2031 avg $30.99 (ROI 64.1), 2032 avg $35.64 (ROI 88.8), 2033 avg $36.16 (ROI 91.5), 2034 avg $35.71 (ROI 89.1), 2035 avg $38.69 (ROI 104.9). The long horizon shows pronounced upside with 2040 avg $59.22 (ROI 213.7) and 2050 avg $118.88 (ROI 529.7). These are estimates, not guarantees, and carry inherent uncertainty.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $29.04, with a min of $21.37 and a max of $42.61. The forecasted ROI is 53.8.
Forecasts show bullish sentiment from 2029 onward, with the 2030 average price at $29.04 and ROI of 53.8, and the 2050 average price at $118.88 with ROI of 529.7.
The 2040 forecast lists a max of $101.37 and an average of $59.22, indicating the possibility of exceeding $100 on the high end.
Bearish sentiment with RSI14 at 40. The 50-day moving average is $19.78 and the 200-day moving average is $23.53. Support is at $18.12 and resistance at $21.78.
Current price is $18.88 and market cap is $832.47M.
Amphastar Pharmaceuticals, Inc. Community Discussion
0Share your Amphastar Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.